PGXL and Silicon Biosystems Collaborate
News Apr 26, 2013
PGXL Technologies and Silicon Biosystems, Inc. announced a collaborative partnership to make the highly regarded Silicon Biosystems DEPArray technology available through PGXL Technologies. The PGXL program will allow clinical researchers and pharma sponsors to obtain the level of data fidelity and resolution needed in cancer biomarker discovery and translational research.
“As the DEPArray technology has gained recognition in the marketplace for its unmatched ability to recover pure cells for molecular characterization, we have received significant interest in having the platform available on a fee-for-service basis,” said Bob Proulx, President and General Manager of Silicon Biosystems’ U.S. operations. “Last year we added a demonstration and training lab, but partnering with PGXL for CRO services will add a whole new dimension to our ability to reach and impact the market.”
The DEPArray technology has broad application in the study of the underlying causes of disease, disease progression and the basis of drug resistance and efficacy. Recent technology progress in the areas of DNA and RNA analysis have shown that the complexity of diseases, like cancer, will require the characterization and comparison of different types of samples at the single cell level. The DEPArray system provides single-cell sorting, and can deliver the cell purity needed for the stringent downstream applications, such as next-gen sequencing and RNA expression profiling.
“We partnered with PGXL because they bring highly complementary capabilities and expertise to the equation,” Proulx continued. “Their experience in molecular methods and operation of a CLIA laboratory make them an ideal service provider for our prospective clients interested in genomic heterogeneity and translational research.”
“PGXL Tech exists to bring to market technologies that advance personalized medicine,” said Dr. Roland Valdes, Jr., President of PGXL Laboratories. “Making the DEPArray available on a fee-for-service basis empowers researchers to work with a precision that will speed discovery.”
Phenogenetic Map Created For Stem Cell Models Of Neurological DiseasesNews
Researchers at The Ohio State University Wexner Medical Center have performed the first meta-analysis of all induced pluripotent stem cell models for neurological and neurodegenerative diseases, and created an atlas of how cell characteristics are linked to their genotype.READ MORE
Fabric Genomics Partners to Improve Pediatric CareNews
Partnerships with Genomics England, Rady Children's Institute for Genomic Medicine, and The Utah Genome Project demonstrate diagnostic utility of Fabric Genomics' algorithm-based genome analysis.READ MORE
Key Cancer-Linked Proteins Thought to be ‘Undruggable’ Until NowNews
A new study published in Nature, conducted by an alliance between industry and academia involving the University of Liverpool, highlights a new approach to targeting key cancer-linked proteins, thought to be ‘undruggable’.READ MORE